HighVista Strategies LLC Has $548,000 Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

HighVista Strategies LLC decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 69.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,496 shares of the biopharmaceutical company's stock after selling 16,841 shares during the quarter. HighVista Strategies LLC's holdings in Intra-Cellular Therapies were worth $548,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Wasatch Advisors LP lifted its holdings in shares of Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock worth $281,601,000 after purchasing an additional 130,351 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Intra-Cellular Therapies by 21.2% in the 2nd quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company's stock worth $205,470,000 after acquiring an additional 525,000 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Intra-Cellular Therapies by 0.6% in the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company's stock worth $181,873,000 after acquiring an additional 14,342 shares during the last quarter. Perceptive Advisors LLC grew its holdings in shares of Intra-Cellular Therapies by 62.6% during the second quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company's stock valued at $117,557,000 after buying an additional 661,052 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its holdings in shares of Intra-Cellular Therapies by 11.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,159,356 shares of the biopharmaceutical company's stock valued at $84,830,000 after buying an additional 116,494 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ITCI. Morgan Stanley lifted their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Royal Bank of Canada boosted their price objective on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an "outperform" rating in a research report on Friday, October 4th. UBS Group lowered their price target on Intra-Cellular Therapies from $83.00 to $79.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. The Goldman Sachs Group lowered their price objective on Intra-Cellular Therapies from $77.00 to $74.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, October 30th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $97.23.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock traded up $0.64 during trading hours on Wednesday, reaching $85.95. The company had a trading volume of 365,475 shares, compared to its average volume of 841,988. The company has a 50 day moving average of $80.90 and a 200 day moving average of $75.90. The firm has a market cap of $9.11 billion, a price-to-earnings ratio of -98.79 and a beta of 0.95. Intra-Cellular Therapies, Inc. has a 1-year low of $58.92 and a 1-year high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). The company had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business's revenue for the quarter was up 39.0% compared to the same quarter last year. During the same period last year, the company earned ($0.25) EPS. As a group, sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Insider Activity at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, President Michael Halstead sold 22,869 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.60% of the stock is owned by corporate insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.